

20 June 2018

## **Deltex Medical Group plc**

### **Result of AGM**

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), announces that all the resolutions proposed at today's AGM were duly passed.

#### **Enquiries**

##### **Deltex Medical Group plc**

Nigel Keen, Chairman

Andy Mears, Chief Executive

Jonathan Shaw, Group Finance Director

01243 774 837

[investorinfo@Deltexmedical.com](mailto:investorinfo@Deltexmedical.com)

##### **Nominated Adviser & Broker**

Arden Partners plc

Chris Hardie

Ciaran Walsh

020 7614 5900

##### **Joint Broker**

Turner Pope Investments (TPI) Ltd

Andy Thacker

0203 621 4120

[info@turnerpope.com](mailto:info@turnerpope.com)

##### **Financial Public Relations**

IFC Advisory Ltd

Tim Metcalfe

Graham Herring

Heather Armstrong

0203 934 6630

#### **Notes for Editors**

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's proprietary ODM (TrueVue™ Doppler) is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only group in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, TrueVue™ Doppler, which is proven to reduce complications suffered by patients after surgery and save hospitals the costs of treating those complications.

Deltex Medical's TrueVue™ System on the CardioQ-ODM+ monitor platform also now provides clinicians with two further advanced haemodynamic monitoring technologies. High Definition Impedance Cardiography is an entirely non-invasive monitoring technology which creates an electrical field across the chest and measures the disruption to this field when the heart pumps blood. Pulse Pressure Waveform Analysis uses peripheral blood pressure signal analysis to give doctors information

on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.

### **Group goal**

Haemodynamic management is now becoming widely accepted as an important major new medical modality. Consequently, the Group's focus is on maximising value from the opportunities presented, as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Group aims to provide clinicians with a single platform, a 'haemodynamic workstation', which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's condition as well as the skill and expertise of the user. Doing this will enable the Group to partner healthcare providers to support modern haemodynamic management across the whole hospital.

The Group is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 40 countries.